Table 1.

Baseline characteristics and clinical course of patients with lung cancers and positive SARS-CoV-2 test

Patients characteristicsPatients (n = 69) no./total no.a (%)
Age
 Median (range), year69 (31–91)
Sex
 Female36/69 (52%)
 Male33/69 (48%)
Race
 White40/69 (58%)
 Black12/69 (17%)
 Asian11/69 (16%)
 Other2/69 (3%)
 Unknown4/69 (6%)
Ethnicity
 Hispanic or Latino8/69 (12%)
 Non–Hispanic or Latino57/69 (82%)
 Unknown4/69 (6%)
Prior smoking historyb
 <5 pack-years25/69 (36%)
 ≥5 pack-years44/69 (64%)
Lung cancer–specific features
 Non–small cell lung cancer64/69 (93%)
 Small-cell lung cancer5/69 (7%)
 Metastatic or active lung cancerc55/69 (80%)
 Prior thoracic surgery or radiotherapy32/69 (46%)
Comorbid conditions
 COPDd12/69 (17%)
 Non-COPD lung diseasee14/69 (20%)
 Obesity (BMI ≥ 30)23/69 (33%)
 Hypertension38/69 (55%)
 Congestive heart failuref5/69 (7%)
 Diabetes mellitus21/69 (30%)
Clinical course
 Hospitalization42/67a (63%)
 Admission to ICU/receipt of intubation/transition to DNI24/65a (37%)
  Admission to ICU15/65a (23%)
  Receipt of intubation and mechanical ventilation13/64a (20%)
  Transition to do not resuscitate/DNIg10/65a (18%)
 Death16/67a (24%)
  • Abbreviations: COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association (Class III, IV, etc.).

  • aDenominators reflect available data; unless specified, unknowns are not included.

  • bFive pack-years was chosen prospectively as a threshold to differentiate those with minor/no tobacco exposure and those with heavy tobacco exposure.

  • cMetastatic or active lung cancer was defined as patients with metastatic lung cancer or patients undergoing active treatment for lung cancer (e.g., neoadjuvant or adjuvant therapy).

  • dCOPD was defined as anyone with this diagnosis listed as a part of past medical history plus either an abnormal pulmonary function test interpreted as consistent with COPD or had inhalers for COPD listed in the outpatient medication record. Patients with only radiologic evidence of COPD or a note in the medical record that the diagnosis was in question were not included.

  • eNon-COPD lung disease was defined as underlying lung disease other than COPD (e.g., reactive airways disease, pneumonitis, abnormal pulmonary function test interpreted as underlying lung disease, etc.).

  • fCongestive heart failure was defined as anyone with NYHA functional class I–IV disease. As such, anyone with this diagnosis listed as a part of the past medical history or an abnormal cardiac echocardiogram demonstrating evidence of structural heart disease consistent with this diagnosis was included.

  • gAn additional 4 patients received intubation and invasive mechanical ventilation and subsequently elected notto receive further necessary intensification of care or interventions.